Profile data is unavailable for this security.
About the company
Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
- Revenue in CNY (TTM)1.17bn
- Net income in CNY-172.33m
- Incorporated2004
- Employees2.60k
- LocationShanghai Medicilon IncNo. 585 Chuanda Road, Pudong New AreaSHANGHAI 201299ChinaCHN
- Phone+86 2 158591500
- Fax+86 2 158596369
- Websitehttps://www.medicilon.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jinyao Pharmaceutical Co Ltd | 3.66bn | 107.59m | 4.32bn | 2.68k | 40.13 | 1.43 | -- | 1.18 | 0.0984 | 0.0984 | 3.35 | 2.76 | 0.5738 | 2.28 | 9.37 | 1,365,219.00 | 2.33 | 1.91 | 4.17 | 3.40 | 42.61 | 46.33 | 4.06 | 3.31 | 0.7584 | 27.18 | 0.2064 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
| Shanghai OPM Biosciences Co Ltd | 254.91m | 49.43m | 4.33bn | 285.00 | 87.82 | 2.01 | -- | 16.98 | 0.4294 | 0.4294 | 2.22 | 18.80 | 0.1095 | 2.07 | 2.54 | 894,431.90 | 2.09 | 4.34 | 2.16 | 4.65 | 58.86 | 58.31 | 19.06 | 23.40 | 19.91 | -- | 0.0315 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
| Assure Tech Hangzhou Co Ltd | 511.29m | 160.91m | 4.39bn | 791.00 | 27.31 | 0.8485 | -- | 8.60 | 1.27 | 1.27 | 4.02 | 40.75 | 0.0799 | 1.52 | 2.67 | 646,379.60 | 2.51 | 31.83 | 2.94 | 38.97 | 38.56 | 65.82 | 31.47 | 47.86 | 8.26 | -- | 0.0166 | 16.05 | -91.84 | 25.18 | -95.35 | 33.51 | 78.77 | -- |
| Yabao Pharmaceutical Group Co Ltd | 2.88bn | 204.43m | 4.41bn | 4.14k | 22.26 | 1.51 | -- | 1.53 | 0.2754 | 0.2754 | 3.81 | 4.05 | 0.7193 | 2.98 | 6.79 | 695,432.10 | 4.52 | 2.82 | 5.90 | 3.97 | 56.00 | 59.20 | 6.29 | 4.19 | 1.62 | 47.13 | 0.0675 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Shanghai Medicilon Inc | 1.17bn | -172.33m | 4.44bn | 2.60k | -- | 1.80 | -- | 3.78 | -1.24 | -1.24 | 9.11 | 18.34 | 0.4205 | 6.63 | 1.64 | 451,437.20 | -6.17 | 9.34 | -7.97 | 11.73 | 12.48 | 36.71 | -14.68 | 14.93 | 2.63 | -- | 0.1229 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 4.46bn | 2.47k | 46.93 | 3.88 | -- | 2.46 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 1.97bn | 97.97m | 4.53bn | 3.37k | 46.16 | 1.78 | -- | 2.30 | 0.652 | 0.652 | 13.10 | 16.92 | 0.4845 | 1.01 | 3.91 | 583,547.80 | 2.38 | 7.38 | 3.23 | 9.60 | 42.51 | 47.03 | 4.92 | 13.53 | 0.894 | 3.37 | 0.3013 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 4.53bn | 447.00 | 26.72 | 1.43 | -- | 4.75 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
Data as of May 31 2024. Currency figures normalised to Shanghai Medicilon Inc's reporting currency: Chinese Yuan Renminbi CNY
8.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harvest Fund Management Co., Ltd.as of 30 Sep 2023 | 1.95m | 1.78% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Sep 2023 | 1.47m | 1.34% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 1.23m | 1.12% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 847.04k | 0.77% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 833.22k | 0.76% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 730.37k | 0.66% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 667.37k | 0.61% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 615.11k | 0.56% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 601.86k | 0.55% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 497.00k | 0.45% |
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
